Dr. Reddy's Laboratories: US DOJ Closes FCPA Inquiry Without Enforcement Action
Dr. Reddy's Laboratories has been notified by the U.S. Department of Justice that its inquiry into potential Foreign Corrupt Practices Act violations has been closed without recommended enforcement action. This follows a similar closure of the SEC's investigation. The company had previously disclosed an investigation into allegations of improper payments to healthcare professionals.
While the closure of the investigation removes a potential legal risk, the initial allegations and investigation process could have had some reputational impact. The absence of enforcement action mitigates further negative impact.
The closure of the inquiry by the U.S. Department of Justice without recommending enforcement action is a positive development for the company, resolving a significant legal uncertainty.
Dr. Reddy's Laboratories Limited has received a letter dated March 5, 2026, from the U.S. Department of Justice, Criminal Division, Fraud Section, stating that the Department has closed its inquiry under the Foreign Corrupt Practices Act (FCPA). Based on the information available to it, the Department has not recommended any enforcement action against the Company.
This announcement follows a previous intimation on February 24, 2026, where the Company informed that it had received a letter from the U.S. Securities and Exchange Commission (SEC) dated February 23, 2026. The SEC had concluded its investigation into allegations of improper payments to healthcare professionals in Ukraine and potentially other countries and did not intend to recommend any enforcement action against the Company at that time.
The Company had initially commenced a detailed investigation into an anonymous complaint regarding these allegations, which could constitute violations of U.S. anti-corruption laws, including the FCPA. This matter was disclosed to the U.S. Department of Justice (DOJ), the U.S. Securities and Exchange Commission (SEC), and the Securities Exchange Board of India (SEBI). A U.S. law firm was engaged to conduct the investigation at the directions of the Company's Board of Directors.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under fraud/defaults disclosure. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.